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Introduction Introduction
Twenty percent of patients with colorectal cancer (CRC) present stage IV disease at the time of diagnosis (1) . Although the curative intent is still possible in a subgroup of these patients, the reported five-year relative survival rate is only 13% (1) . The surgical approach of colorectal liver metastases (CRLMs) changes dramatically during the latest years, with a reported postoperative mortality less than 1% (2) . The resectability of CRLMs is characterized by the technical possibility to remove all the visible metastases while preserving an adequate future liver remnant volume (FLRV) with its corresponding vascular supply and biliary drainage (3) . Nowadays, to recruit more patients for surgical resection, neoadjuvant chemotherapy to downsize the tumors and adjunctive techniques to increase the FLRV are combined (2) . In the absence of surgical resection, a median survival of less than one year was reported after diagnosis of CRLMs (4) .
According to the evidence coming from tertiary centers, Crohn's disease increases 20 times the risk of colorectal cancer, up to 1.2% (5, 6) , and worsens the patients' prognosis (7). Liver oligometastasis, usually defined as fewer than five nodules, should be seen as an intermediate state between localized and polymetastasic disease, with an in-between prognosis (8) .
The objective of this case report is to illustrate the surgical resection of a large liver metachronous metastasis of colon cancer origin in a patient with Crohn's disease.
Case report Case report
A 53-year old female patient was admitted to our hospital for a colon cancer metachronous liver metastasis. The Fig. 1 ). Open surgical resection was decided, using a J-shape incision. A right hemihepatectomy was performed, using Pringle maneuver for 30 minutes (see Fig. 2 ). The patient was discharged after 12 days, without additional morbidities.
Discussions Discussions
We presented the case of surgical resection of a large liver metachronous metastasis of colon cancer origin in a patient with severe Crohn's disease.
Although seen as a more indolent disease, the metachronous CRLMs carry a similar prognosis with the synchronous disease, as long as an R0 resection is achieved (9) . The postoperative and long-term oncological outcomes were similar between the two groups even in patients with more than four lesions (10). Hackl et al. published a ten-year population-based analysis of 5772 cases of primary CRC, using data from a German tumor registry (4). CRLMs were observed in 1426 patients (24.7%). 407 patients, representing 28.5% from the CRLMs population and 7.05% of all patients, presented metachronous disease. On multivariate analysis, there was no difference in overall survival between synchronous versus metachronous disease (P=0.799). Of particular importance was that resected patients with a single CRLM had a similar 10-year overall survival with non-metastatic patients (28.3% versus 29.8%, P=ns) (4). On the other hand, Pawlik and colleagues showed that tumor biology rather than surgical technique determine prognosis in CRLMs (see Table 1 ) (11). Historically, a 1-cm resection margin was considered associated with better outcomes following CRLMs resection (13) . The current evidence showed that a margin clearance of 1-4 mm is associated with improved survival compared to R1 only for wild-type KRAS tumors (14) . In cases of mutated KRAS tumors were observed no differences between R1 resections or a clearance margin of 1-4, 5-9, or ≥ 10 mm (14) . As a strategy for resection, the parenchymal-sparing hepatectomy can be performed safely without compromising oncological outcomes, even for deep-placed or advanced (≥ four lesions with a diameter ≤50 mm) CRLMs (15, 16) . Compared to major hepatectomy, the parenchymal-sparing resection is associated with a larger number of ligatures, a longer transection time, and a wider raw transected area (16) .
Spelt et al. investigated the characteristics of primary tumor predictive for survival after liver resection for colon cancer metastases (17) . Predictive factors for overall survival (OS) were the vascular and perineural invasion of the primary CRC tumor, the size of the largest metastasis, and severe complications after hepatic resection. The disease-free survival (DFS) was predicted by perineural invasion, the number of hepatic metastases, and preoperative CEA (17) . Lymph node ratio was an independent predictive factor only for DFS (17) . Serrablo et al. showed that three or more metastatic lesions, R1 resections, and less than 50% tumor necrosis are associated with a worse OS; the only independent prognostic factor in the multivariate analysis was ≥ 3 liver lesions (18) . The French Colorectal Liver Metastases Working Group investigated the factors associated with recurrence after initial hepatectomy for CRLMs (19) . The tumor recurrence occurred in 47.4% of 2320 included patients, with a majority of 89.1% during the first three years. The tumor recurrence was intrahepatic, extra-hepatic, and combined in 46.2%, 31.8%, and 22%, respectively. The factors associated with recurrence after an initial hepatectomy for CRLMs were node-positive primary CRC (HR 1.27, 95%CI 1.09-1.49), > three liver metastases (HR 1.27, 95%CI 1.06-1.52) and diameter of the largest metastasis > 4 cm (HR 1.19, 95%CI 1.01-1.43) (19) .
Larsen et al. evaluated the survival of patients with Crohn's disease and colorectal cancer (CD-CRC) (7) . In this nationwide population-based Danish study were included 100 CD-CRC patients and 71438 patients with CRC and without CD. Although the patients with CD were younger at the time of diagnosis, the stage distribution was similar between the two groups (7). The survival rate of patients with CD-CRC was lower especially in the first year after diagnosis (54% versus 60%) (7) . Another analysis of Danish medical registries, including 238 patients with CD-CRC and 107024 patients without inflammatory bowel disease showed a higher rate of stage III (21% versus 27%) and IV patients (23% versus 21%), with a lower five-year overall survival of 38% for CD-CRC compared to 41% of patients with CRC and ulcerative colitis, and 44% for CRC patients without CD (20) . Dugum et al. presented 44 patients with inflammatory bowel diseases (IBD) and colorectal cancer (CRC), propensity score-matched with 176 CRC patients without IBD (21) . There were no differences between the two groups regarding tumor recurrences (23% vs. 19%, P=0.074), disease-free survival (Hazard ratio [HR] = 0.60, P=0.074), and overall survival (HR=0.87, P=0.58) (21) . An analysis of 33 patients with Crohn's disease and colorectal cancer revealed a comparable clinicopathological and molecular profile to sporadic colorectal cancer (22) . Colorectal cancer in patients with Crohn's disease was BRAF (97%) and NRAS (100%) wild-type, microsatellite stable in 94% of cases and KRAS mutated in 18% of cases. A history of Crohn's disease longer than 25 years was associated with significantly shorter overall survival (P=0.0029) (22) .
Conclusions Conclusions
Patients with liver metastases of colorectal origin in the presence of Crohn's disease come with significant clinical challenges. Inside the multimodality approach, liver resection represents the therapeutic approach associated with the best long-term oncological results. 
